PeproMene Bio, Inc. Announced Complete Response of The First P...
- Written by LATEST ASIANET NEWS RELEASES
- Published in Asia Net
IRVINE, Calif., Dec. 21, 2022 /PRNewswire-AsiaNet/ -- PeproMene Bio, Inc., a clinical-stage biotech company developing novel therapies to treat cancers and immune disorders, today announced that the first patient treated in its phase 1 relapsed or refractory B-cell Non-Hodgkin Lymphoma (r/r B-NHL) cl...
Authors: LATEST ASIANET NEWS RELEASES